> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Inspection at Laurus Labs Ends in 2-item 483
- URL: https://www.fdaweb.com/inspection-at-laurus-labs-ends-in-2-item-483/
- Published: 2023-02-13T12:00:00.000Z
- Updated: 2026-09-14T18:15:37.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153767

FDA has completed an inspection of a Laurus Labs formulations manufacturing facility (Visakhapatnam, Andhra Pradesh, India. The inspection was conducted 2/6-10 and resulted in a Form 483 with two undisclosed observations, a [company release](https://www.lauruslabs.com/Investors/PDF/Disclosures/USFDAInspectionUnit-2.pdf?ref=fdaweb.com) says, adding that they were “procedural in nature,” It says the observations will be addressed within the “stipulated timelines.”

Laurus says it works with all the top 10 generic pharmaceutical companies in the world, and that it sells its active pharmaceutical ingredients in 56 countries. “Our major focus areas include anti-retroviral, hepatitis C and oncology drugs,” it adds.